REFERENCES
1. Shah JP. Jatin shah’s head and neck surgery and oncology. 5th ed. St. Louis, MO: Elsevier Inc.; 2019.
2. Vauterin TJ, Veness MJ, Morgan GJ, Poulsen MG, O’Brien CJ. Patterns of lymph node spread of cutaneous squamous cell carcinoma of the head and neck. Head Neck 2006;28:785-91.
3. Marks NJ. The anatomy of the lymph nodes of the parotid gland. Clin Otolaryngol Allied Sci 1984;9:271-5.
4. Pisani P, Ramponi A, Pia F. The deep parotid lymph nodes: an anatomical and oncological study. J Laryngol Otol 1996;110:148-50.
5. Stonesifer CJ, Djavid AR, Grimes JM, et al. Immune checkpoint inhibition in non-melanoma skin cancer: a review of current evidence. Front Oncol 2021;11:734354.
6. Franzen A, Buchali A, Lieder A. The rising incidence of parotid metastases: our experience from four decades of parotid gland surgery. Acta Otorhinolaryngol Ital 2017;37:264-9.
7. Swanson MS, Sinha UK. Diagnosis and management of merkel cell carcinoma of the head and neck: current trends and controversies. Cancers (Basel) 2014;6:1256-66.
8. McLean T, Brunner M, Ebrahimi A, et al. Concurrent primary and metastatic cutaneous head and neck squamous cell carcinoma: Analysis of prognostic factors. Head Neck 2013;35:1144-8.
9. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 2013;149:541-7.
10. Khurana VG, Mentis DH, O’brien CJ, Hurst TL, Stevens GN, Packham NA. Parotid and neck metastases from cutaneous squamous cell carcinoma of the head and neck. Am J Surg 1995;170:446-50.
11. Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008;9:713-20.
12. Karia PS, Morgan FC, Ruiz ES, Schmults CD. Clinical and incidental perineural invasion of cutaneous squamous cell carcinoma: a systematic review and pooled analysis of outcomes data. JAMA Dermatol 2017;153:781-8.
13. Rowe DE, Carroll RJ, Day CL. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. J Am Acad Dermatol 1992;26:976-90.
14. Newlands C, Currie R, Memon A, Whitaker S, Woolford T. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016;130:S125-32.
15. Haug K, Breuninger H, Metzler G, et al. Prognostic impact of perineural invasion in cutaneous squamous cell carcinoma: results of a prospective study of 1399 tumors. J Invest Dermatol 2020;140:1968-75.
16. Thompson AK, Kelley BF, Prokop LJ, Murad MH, Baum CL. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol 2016;152:419-28.
17. Stratigos AJ, Garbe C, Dessinioti C, et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. Eur J Cancer 2020;128:60-82.
18. Harris BN, Bayoumi A, Rao S, Moore MG, Farwell DG, Bewley AF. Factors Associated with Recurrence and Regional Adenopathy for Head and Neck Cutaneous Squamous Cell Carcinoma. Otolaryngol Head Neck Surg 2017;156:863-9.
19. Kearney L, Hogan D, Conlon P, Roche M, O’Neill JP, O’Sullivan JB. High-risk cutaneous malignancies and immunosuppression: Challenges for the reconstructive surgeon in the renal transplant population. J Plast Reconstr Aesthet Surg 2017;70:922-30.
20. Southwell KE, Chaplin JM, Eisenberg RL, McIvor NP, Morton RP. Effect of immunocompromise on metastatic cutaneous squamous cell carcinoma in the parotid and neck. Head Neck 2006;28:244-8.
21. Yilmaz M, Eskiizmir G, Friedman O. Cutaneous squamous cell carcinoma of the head and neck: management of the parotid and neck. Facial Plast Surg Clin North Am 2012;20:473-81.
22. Sahovaler A, Krishnan RJ, Yeh DH, et al. Outcomes of cutaneous squamous cell carcinoma in the head and neck region with regional lymph node metastasis: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg 2019;145:352-60.
23. Porceddu SV, Bressel M, Poulsen MG, et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase iii trog 05.01 trial. J Clin Oncol 2018;36:1275-83.
24. Ch’ng S, Maitra A, Allison RS, et al. Parotid and cervical nodal status predict prognosis for patients with head and neck metastatic cutaneous squamous cell carcinoma. J Surg Oncol 2008;98:101-5.
25. Robsahm TE, Helsing P, Veierød MB. Cutaneous squamous cell carcinoma in Norway 1963-2011: increasing incidence and stable mortality. Cancer Med 2015;4:472-80.
26. Bichakjian CK, Olencki T, Aasi SZ, et al. Merkel cell carcinoma, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2018;16:742-74.
27. Deneve JL, Messina JL, Marzban SS, et al. Merkel cell carcinoma of unknown primary origin. Ann Surg Oncol 2012;19:2360-6.
28. Vandeven N, Lewis CW, Makarov V, et al. Merkel cell carcinoma patients presenting without a primary lesion have elevated markers of immunity, higher tumor mutation burden, and improved survival. Clin Cancer Res 2018;24:963-71.
29. Rizzo JM, Harms PW, Harms KL, Plaska A, Brenner C, Durham AB. Unknown primary Merkel cell carcinoma in the immunosuppressed patient: Case series. JAAD Case Rep 2021;8:19-22.
30. Pan Z, Chen YY, Wu X, et al. Merkel cell carcinoma of lymph node with unknown primary has a significantly lower association with Merkel cell polyomavirus than its cutaneous counterpart. Mod Pathol 2014;27:1182-92.
31. Bajetta E, Celio L, Platania M, et al. Single-institution series of early-stage Merkel cell carcinoma: long-term outcomes in 95 patients managed with surgery alone. Ann Surg Oncol 2009;16:2985-93.
32. Fagan J, Brooks J, Ramsey ML. Basal cell cancer. Treasure Island, FL: StatPearls, 2022.
33. Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol 2013;149:615-6.
34. Morgan FC, Ruiz ES, Karia PS, Besaw RJ, Neel VA, Schmults CD. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter. J Am Acad Dermatol 2020;83:832-8.
35. McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer 2014;50:774-83.
36. Nguyen-Nielsen M, Wang L, Pedersen L, et al. The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010. Eur J Dermatol 2015;25:463-8.
37. Martinez SR, Barr KL, Canter RJ. Rare tumors through the looking glass: an examination of malignant cutaneous adnexal tumors. Arch Dermatol 2011;147:1058-62.
38. Storino A, Drews RE, Tawa NE Jr. Malignant cutaneous adnexal tumors and role of SLNB. J Am Coll Surg 2021;232:889-98.
39. Barnes M, Hestley A, Murray DR, Carlson GW, Parker D, Delman KA. The risk of lymph node involvement in malignant cutaneous adnexal tumors. Am Surg 2014;80:270-4.
40. Ogata D, Kiyohara Y, Yoshikawa S, Kasami M. Treatment strategy for cutaneous apocrine carcinoma. Int J Clin Oncol 2014;19:712-5.
41. Conic RRZ, Damiani G, Frigerio A, et al. Incidence and outcomes of cutaneous angiosarcoma: A SEER population-based study. J Am Acad Dermatol 2020;83:809-16.
42. Wollina U, Schönlebe J, Bujok V, et al. Dermal pleomorphic sarcoma of the scalp - report of two cases. Open Access Maced J Med Sci 2019;7:2982-4.
44. Sood A, Wykes J, Roshan D, et al. A critical analysis of the prognostic performance of the 8th edition American Joint Committee on Cancer staging for metastatic cutaneous squamous cell carcinoma of the head and neck. Head Neck 2019;41:1591-6.
45. Moody SA, Hirsch BE, Myers EN. Squamous cell carcinoma of the external auditory canal: an evaluation of a staging system. Am J Otol 2000;21:582-8.
46. Ruiz ES, Karia PS, Besaw R, Schmults CD. Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. JAMA Dermatol 2019;155:819-25.
47. Roscher I, Falk RS, Vos L, et al. Validating 4 staging systems for cutaneous squamous cell carcinoma using population-based data: a nested case-control study. JAMA Dermatol 2018;154:428-34.
48. Luk PP, Ebrahimi A, Veness MJ, et al. Prognostic value of the 8th edition American Joint Commission Cancer nodal staging system for patients with head and neck cutaneous squamous cell carcinoma: A multi-institutional study. Head Neck 2021;43:558-67.
49. Ebrahimi A, Luk PP, Low H, et al. The American Joint Committee on Cancer staging for metastatic head and neck cutaneous squamous cell carcinoma: A multi-institutional study of within-stage heterogeneity and impact on prognostic performance. Head Neck 2020;42:3235-42.
50. Amit M, Liu C, Gleber-Netto FO, et al. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer 2021;127:1238-45.
51. Sood A, Wykes J, Roshan D, et al. Number of nodal metastases and prognosis in metastatic cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg 2019;89:863-7.
52. Lubov J, Labbé M, Sioufi K, et al. Prognostic factors of head and neck cutaneous squamous cell carcinoma: a systematic review. J Otolaryngol Head Neck Surg 2021;50:54.
53. Clark JR, Rumcheva P, Veness MJ. Analysis and comparison of the 7th edition American Joint Committee on Cancer (AJCC) nodal staging system for metastatic cutaneous squamous cell carcinoma of the head and neck. Ann Surg Oncol 2012;19:4252-8.
54. Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol 2014;32:327-34.
55. Forest VI, Clark JJ, Veness MJ, Milross C. N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers. Cancer 2010;116:1298-304.
56. O’Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS, Jackson MA. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 2002;24:417-22.
57. Oddone N, Morgan GJ, Palme CE, et al. Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer 2009;115:1883-91.
58. Moshiri AS, Nghiem P. Milestones in the staging, classification, and biology of Merkel cell carcinoma. J Natl Compr Canc Netw 2014;12:1255-62.
59. Heppt MV, Steeb T, Berking C, Nast A. Comparison of guidelines for the management of patients with high-risk and advanced cutaneous squamous cell carcinoma - a systematic review. J Eur Acad Dermatol Venereol 2019;33 Suppl 8:25-32.
60. Givi B, Andersen PE, Diggs BS, Wax MK, Gross ND. Outcome of patients treated surgically for lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Head Neck 2011;33:999-1004.
61. O’Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS. Incidence of cervical node involvement in metastatic cutaneous malignancy involving the parotid gland. Head Neck 2001;23:744-8.
62. Thom JJ, Moore EJ, Price DL, Kasperbauer JL, Starkman SJ, Olsen KD. The role of total parotidectomy for metastatic cutaneous squamous cell carcinoma and malignant melanoma. JAMA Otolaryngol Head Neck Surg 2014;140:548-54.
63. Wong WK, Morton RP. Elective management of cervical and parotid lymph nodes in stage N0 cutaneous squamous cell carcinoma of the head and neck: a decision analysis. Eur Arch Otorhinolaryngol 2014;271:3011-9.
64. Peiffer N, Kutz JW Jr, Myers LL, et al. Patterns of regional metastasis in advanced stage cutaneous squamous cell carcinoma of the auricle. Otolaryngol Head Neck Surg 2011;144:36-42.
65. Yoon M, Chougule P, Dufresne R, Wanebo HJ. Localized carcinoma of the external ear is an unrecognized aggressive disease with a high propensity for local regional recurrence. Am J Surg 1992;164:574-7.
66. Mazzoni A, Danesi G, Zanoletti E. Primary squamous cell carcinoma of the external auditory canal: surgical treatment and long-term outcomes. Acta Otorhinolaryngol Ital 2014;34:129-37.
67. Kadakia S, Saman M, Gordin E, Marra D, Ducic Y. The role of parotidectomy in the treatment of auricular squamous cell carcinoma. Otolaryngol Head Neck Surg 2015;152:1048-52.
68. Kadakia S, Ducic Y, Marra D, Saman M. The role of elective superficial parotidectomy in the treatment of temporal region squamous cell carcinoma. Oral Maxillofac Surg 2016;20:143-7.
69. Skulsky SL, O’Sullivan B, McArdle O, et al. Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines in Oncology. Head Neck 2017;39:578-94.
70. Amit M, Liu C, Mansour J, et al. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer 2021;127:4413-20.
71. Tremblay-Abel V, Poulin MA, Blouin MM, Parent F, Perron É. Sentinel lymph node biopsy in high-risk cutaneous squamous cell carcinoma: analysis of a large size retrospective series. Dermatol Surg 2021;47:908-13.
72. Keohane SG, Botting J, Budny PG, et al. British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020. Br J Dermatol 2021;184:401-14.
73. Sapijaszko M, Zloty D, Bourcier M, Poulin Y, Janiszewski P, Ashkenas J. Canadian Non-melanoma Skin Cancer Guidelines Committee. Non-melanoma skin cancer in Canada chapter 5: management of squamous cell carcinoma. J Cutan Med Surg 2015;19:249-59.
74. Harwood M, Wu H, Tanabe K, Bercovitch L. Metastatic basal cell carcinoma diagnosed by sentinel lymph node biopsy. J Am Acad Dermatol 2005;53:475-8.
75. Picon AI, Coit DG, Shaha AR, et al. Sentinel lymph node biopsy for cutaneous head and neck melanoma: mapping the parotid gland. Ann Surg Oncol 2016;23:9001-9.
77. Hirshoren N, Ruskin O, McDowell LJ, Magarey M, Kleid S, Dixon BJ. Management of Parotid Metastatic Cutaneous Squamous Cell Carcinoma: Regional Recurrence Rates and Survival. Otolaryngol Head Neck Surg 2018;159:293-9.
78. Audet N, Palme CE, Gullane PJ, et al. Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome. Head Neck 2004;26:727-32.
79. Ebrahimi A, Moncrieff MD, Clark JR, et al. Predicting the pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck based on location of the primary. Head Neck 2010;32:1288-94.
80. Olsen KD, Quer M, de Bree R, Vander Poorten V, Rinaldo A, Ferlito A. Deep lobe parotidectomy-why, when, and how? Eur Arch Otorhinolaryngol 2017;274:4073-8.
81. Cracchiolo JR, Shaha AR. Parotidectomy for Parotid Cancer. Otolaryngol Clin North Am 2016;49:415-24.
82. Veness MJ, Porceddu S, Palme CE, Morgan GJ. Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodes. Head Neck 2007;29:621-31.
83. Goh RY, Bova R, Fogarty GB. Cutaneous squamous cell carcinoma metastatic to parotid - analysis of prognostic factors and treatment outcome. World J Surg Oncol 2012;10:117.
84. Shao A, Wong DK, McIvor NP, et al. Parotid metastatic disease from cutaneous squamous cell carcinoma: prognostic role of facial nerve sacrifice, lateral temporal bone resection, immune status and P-stage. Head Neck 2014;36:545-50.
85. Woods RSR, Naude A, O’Sullivan JB, et al. Management of temporal bone malignancy in treland. J Neurol Surg B Skull Base 2020;81:680-5.
86. Esclamado RM, Carroll WR. Extracapsular spread and the perineural extension of squamous cell cancer in the cervical plexus. Arch Otolaryngol Head Neck Surg 1992;118:1157-8.
87. Yesensky J, Solis RN, Bewley A. Facial nerve sacrifice during parotidectomy for metastatic cutaneous squamous cell carcinoma. OTO Open 2021;5:2473974X21996627.
88. Solares CA, Lee K, Parmar P, O’Rourke P, Panizza B. Epidemiology of clinical perineural invasion in cutaneous squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 2012;146:746-51.
89. Panizza B, Solares CA, Redmond M, Parmar P, O’Rourke P. Surgical resection for clinical perineural invasion from cutaneous squamous cell carcinoma of the head and neck. Head Neck 2012;34:1622-7.
90. Warren TA, Panizza B, Porceddu SV, et al. Outcomes after surgery and postoperative radiotherapy for perineural spread of head and neck cutaneous squamous cell carcinoma. Head Neck 2016;38:824-31.
91. Solares CA, Mason E, Panizza BJ. Surgical management of perineural spread of head and neck cancers. J Neurol Surg B Skull Base 2016;77:140-9.
92. Kwok HC, Morton RP, Chaplin JM, McIvor NP, Sillars HA. Quality of life after parotid and temporal bone surgery for cancer. Laryngoscope 2002;112:820-33.
93. Swendseid BP, Philips RHW, Rao NK, et al. The underappreciated role of auriculotemporal nerve involvement in local failure following parotidectomy for cancer. Head Neck 2020;42:3253-62.
94. Iwanaga J, Fisahn C, Watanabe K, et al. Parotid Branches of the Auriculotemporal Nerve: An Anatomical Study With Implications for Frey Syndrome. J Craniofac Surg 2017;28:262-4.
95. Tansatit T, Apinuntrum P, Phetudom T. Evidence suggesting that the buccal and zygomatic branches of the facial nerve May contain parasympathetic secretomotor fibers to the parotid gland by means of communications from the auriculotemporal nerve. Aesthetic Plast Surg 2015;39:1010-7.
96. Lebbe C, Becker JC, Grob JJ, et al. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer 2015;51:2396-403.
97. Amin MB, Edge SB, Gress DM, et al. American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual. 8th ed.Chicago, IL, USA: American Joint Committee on Cancer, Springer, 2017.
98. Lee JS, Durham AB, Bichakjian CK, et al. Completion lymph node dissection or radiation therapy for sentinel node metastasis in merkel cell carcinoma. Ann Surg Oncol 2019;26:386-94.
99. Al-Hakami H, Awad BI, Al-Garni M, Al-Maghrabi HA, Al-Shareef N. Apocrine carcinoma of the scalp with neck lymph node metastasis: A case report and review of the literature. J Family Med Prim Care 2019;8:3758-62.
100. Casso C, Kwhaja S, Davies S, Al-Ani Z, Saeed SR, Homer JJ. Effect of temporal bone resection on temporomandibular joint function: a quality of life study. Otolaryngol Head Neck Surg 2010;142:85-9.
101. Haymerle G, Enzenhofer E, Lechner W, et al. The effect of adjuvant radiotherapy on radial forearm free flap volume after soft palate reconstruction in 13 patients. Clin Otolaryngol 2018;43:742-5.
102. Rowe D, Emmett J. Reconstruction of the Base of Skull Defect-Lessons Learned over 25 Combined Years. J Neurol Surg B Skull Base 2016;77:161-8.
103. Rosenthal EL, King T, McGrew BM, Carroll W, Magnuson JS, Wax MK. Evolution of a paradigm for free tissue transfer reconstruction of lateral temporal bone defects. Head Neck 2008;30:589-94.
104. Urban MJ, Eggerstedt M, Varelas E, et al. Hypoglossal and Masseteric Nerve Transfer for Facial Reanimation: A Systematic Review and Meta-Analysis. Facial Plast Surg Aesthet Med 2022;24:10-7.
105. Herman MP, Amdur RJ, Werning JW, Dziegielewski P, Morris CG, Mendenhall WM. Elective neck management for squamous cell carcinoma metastatic to the parotid area lymph nodes. Eur Arch Otorhinolaryngol 2016;273:3875-9.
106. Nottage MK, Lin C, Hughes BG, et al. Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck 2017;39:679-83.
107. Wang JT, Palme CE, Morgan GJ, Gebski V, Wang AY, Veness MJ. Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. Head Neck 2012;34:1524-8.
108. Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope 2005;115:870-5.
109. Porceddu SV, Daniels C, Yom SS, et al. Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the Delivery of Postoperative Radiation Therapy in Complex Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN). Int J Radiat Oncol Biol Phys 2020;107:641-51.
110. Tanvetyanon T, Padhya T, McCaffrey J, et al. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck 2015;37:840-5.
111. Goyal U, Prabhakar NK, Davuluri R, Morrison CM, Yi SK. Role of Concurrent Systemic Therapy with Adjuvant Radiation Therapy for Locally Advanced Cutaneous Head and Neck Squamous Cell Carcinoma. Cureus 2017;9:e1784.
112. Lavaud J, Blom A, Longvert C, Fort M, Funck-Brentano E, Saiag P. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma. Eur J Dermatol 2019;29:636-40.
113. Joseph K, Walker J, Raziee H, Faruqi S, Smylie M. PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma. J Cutan Med Surg 2022;26:243-8.
114. Vaidya P, Mehta A, Ragab O, Lin S, In GK. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep 2019;5:763-6.
115. Bishop AJ, Garden AS, Gunn GB, et al. Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. Head Neck 2016;38 Suppl 1:E452-8.
116. Strom T, Naghavi AO, Messina JL, et al. Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck. Head Neck 2017;39:48-55.
117. Gunaratne DA, Howle JR, Veness MJ. Sentinel lymph node biopsy in Merkel cell carcinoma: a 15-year institutional experience and statistical analysis of 721 reported cases. Br J Dermatol 2016;174:273-81.
118. Lok B, Khan S, Mutter R, et al. Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. Cancer 2012;118:3937-44.
119. Tseng YD, Apisarnthanarax S, Liao JJ, Bhatia S, Nghiem PT, Parvathaneni U. Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: a survey of US-based radiation oncologists. Expert Rev Anticancer Ther 2017;17:281-7.
120. Jouary T, Leyral C, Dreno B, et al. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol 2012;23:1074-80.
121. Cook MM, Schaub SK, Goff PH, et al. Postoperative, Single-Fraction Radiation Therapy in Merkel Cell Carcinoma of the Head and Neck. Adv Radiat Oncol 2020;5:1248-54.
122. Bhatia S, Storer BE, Iyer JG, et al. Adjuvant radiation therapy and chemotherapy in merkel cell carcinoma: survival analyses of 6908 cases from the national cancer data base. J Natl Cancer Inst 2016;108:djw042.
123. Rush Z, Fields RC, Lee N, Brownell I. Radiation therapy in the management of Merkel cell carcinoma: current perspectives. Expert Rev Dermatol 2011;6:395-404.
124. Płachta I, Kleibert M, Czarnecka AM, Spałek M, Szumera-Ciećkiewicz A, Rutkowski P. Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation. Int J Mol Sci 2021;22:5077.
125. Płachta I, Kleibert M, Czarnecka AM, Spałek M, Szumera-Ciećkiewicz A, Rutkowski P. Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation. Int J Mol Sci 2021;22:4759.
126. Dessinioti C, Plaka M, Soura E, et al. A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors. Oncologist 2019;24:e755-64.
127. D’Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer 2021;9:e002646.
128. Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. J Clin Oncol 2020;38:2476-87.
129. Cowey CL, Robert NJ, Espirito JL, et al. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy. Cancer Med 2020;9:7381-7.
130. Migden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 2018;379:341-51.
131. Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 2021;32:1276-85.
132. Maubec E, Boubaya M, Petrow P, et al. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. J Clin Oncol 2020;38:3051-61.
